ImmunoGen (IMGN) Receiving Somewhat Positive Press Coverage, Accern Reports
Press coverage about ImmunoGen (NASDAQ:IMGN) has trended somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ImmunoGen earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 46.1820343446356 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Zacks: Brokerages Anticipate ImmunoGen, Inc. (IMGN) Will Announce Quarterly Sales of $15.37 Million (americanbankingnews.com)
- ImmunoGen (IMGN) Research Coverage Started at Piper Jaffray Companies (americanbankingnews.com)
- Zacks: Brokerages Expect ImmunoGen, Inc. (IMGN) to Announce -$0.30 Earnings Per Share (americanbankingnews.com)
- Brokers Opinions on: ImmunoGen, Inc. (NASDAQ:IMGN) (newburghpress.com)
- Immunogen Inc (IMGN) Stand Above PSAR Line (cantoncaller.com)
Several research firms have recently issued reports on IMGN. BidaskClub cut ImmunoGen from a “hold” rating to a “sell” rating in a report on Friday, July 27th. Zacks Investment Research upgraded ImmunoGen from a “sell” rating to a “hold” rating in a report on Monday, August 27th. Cowen restated a “hold” rating on shares of ImmunoGen in a report on Thursday, May 17th. HC Wainwright set a $18.00 price objective on ImmunoGen and gave the stock a “buy” rating in a report on Tuesday, June 5th. Finally, ValuEngine cut ImmunoGen from a “strong-buy” rating to a “buy” rating in a report on Friday, June 8th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $12.42.
ImmunoGen (NASDAQ:IMGN) last issued its earnings results on Friday, July 27th. The biotechnology company reported ($0.31) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.02). The company had revenue of $9.29 million during the quarter, compared to analysts’ expectations of $14.12 million. During the same quarter in the prior year, the firm earned ($0.10) EPS. The company’s revenue was down 76.2% compared to the same quarter last year. sell-side analysts predict that ImmunoGen will post -1.2 EPS for the current year.
ImmunoGen, Inc, a clinical-stage biotechnology company, focuses on developing antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm, as well as coltuximab ravtansine, a CD19-targeting ADC, which is in Phase II trial for DLBCL.
See Also: Using the New Google Finance Tool
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.